RhumbLine Advisers’s Royalty Pharma RPRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $16.1M | Sell |
447,240
-2,724
| -0.6% | -$98.1K | 0.01% | 821 |
|
|
2025
Q1 | $14M | Sell |
449,964
-4,184
| -0.9% | -$130K | 0.01% | 870 |
|
|
2024
Q4 | $11.6M | Sell |
454,148
-3,362
| -0.7% | -$85.8K | 0.01% | 985 |
|
|
2024
Q3 | $12.9M | Buy |
457,510
+10,429
| +2% | +$295K | 0.01% | 945 |
|
|
2024
Q2 | $11.8M | Sell |
447,081
-11,165
| -2% | -$294K | 0.01% | 950 |
|
|
2024
Q1 | $13.9M | Buy |
458,246
+2,490
| +0.5% | +$75.6K | 0.01% | 888 |
|
|
2023
Q4 | $12.8M | Sell |
455,756
-5,543
| -1% | -$156K | 0.01% | 928 |
|
|
2023
Q3 | $12.5M | Sell |
461,299
-14,018
| -3% | -$380K | 0.01% | 882 |
|
|
2023
Q2 | $14.6M | Buy |
475,317
+57,011
| +14% | +$1.75M | 0.02% | 809 |
|
|
2023
Q1 | $15.1M | Buy |
418,306
+7,164
| +2% | +$258K | 0.02% | 755 |
|
|
2022
Q4 | $16.2M | Buy |
411,142
+24,889
| +6% | +$984K | 0.02% | 693 |
|
|
2022
Q3 | $15.5M | Buy |
386,253
+41,475
| +12% | +$1.67M | 0.02% | 660 |
|
|
2022
Q2 | $14.5M | Buy |
344,778
+67,171
| +24% | +$2.82M | 0.02% | 710 |
|
|
2022
Q1 | $10.8M | Sell |
277,607
-5,056
| -2% | -$197K | 0.01% | 918 |
|
|
2021
Q4 | $11.3M | Buy |
282,663
+10,161
| +4% | +$405K | 0.01% | 924 |
|
|
2021
Q3 | $9.85M | Sell |
272,502
-16,754
| -6% | -$605K | 0.01% | 964 |
|
|
2021
Q2 | $11.9M | Sell |
289,256
-7,547
| -3% | -$309K | 0.02% | 900 |
|
|
2021
Q1 | $12.9M | Buy |
296,803
+199,442
| +205% | +$8.7M | 0.02% | 836 |
|
|
2020
Q4 | $4.87M | Buy |
97,361
+20,592
| +27% | +$1.03M | 0.01% | 1367 |
|
|
2020
Q3 | $3.23M | Buy |
+76,769
| New | +$3.23M | 0.01% | 1421 |
|